Awarded contract

Gene testing and reporting for Ovarian cancer specimens

Details

Supplier(s)
Myriad Genetics
Value
£363,000
Topic
Services provided by medical laboratories
Published
19 November 2026

Tender description

NHS Greater Glasgow and Clyde, Laboratory Genetics requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026. Lot 1: NHS Greater Glasgow and Clyde requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. The technical processing and laboratory reporting must be validated to ISO 15189 (2022) standards or equivalent and the underlying technology used must be clinically validated with demonstrable assessment against clinical outcomes. The service must have a robust trackability process to ensure that FFPE blocks are processed sensitively and returned to Laboratory Genetics NHS GGC. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026. The provider must be able to meet NHS GGC boards Information Technology and Security and Information Governance frameworks by completion of Data Protection Impact Assessment (DPIA), and establishing a Data Processing Agreement (DPA) along with a Systems Security Policy (SSP) as applicable. All information governance, cyber-security and any contractual agreements must be established and in place by 01/12/2026 as the current HRD service, based within the UK, will cease to exist from 01/12/2026. The supplier must be able to provide a fixed cost per test, between 01/12/2026-31/12/2027. There are no Scottish Genomic Laboratories able to provide this test. We require a rapid solution to ensure that patients needing the HRD test can access the test and associated treatment pathways based on the test result. Not having a test available for this patient cohort will lead to significant patient harm and even early death. Additional information: Contract valid 01/12/2026 - 31/12/2027

Timeline

  1. Awarded contractThis notice (current page)
    Published
    19 Nov 2026
    Award
    12 Nov 2026

About the buyer

NHS Greater Glasgow and Clyde is a Scottish healthcare board with its own Procurement Department. National contracts are used wherever possible, drawn from National Procurement, part of NHS National Services Scotland. Scottish Procurement frameworks and Crown Commercial Service contracts cover much of the rest. Pharmacy, capital planning, eHealth and estates each manage their own specialist procurement.

Over the past 5 years, most of NHS Greater Glasgow and Clyde's contract awards have been in architectural and engineering services, business services and health and social work.

AI insights

  • Is Myriad Genetics their go-to supplier?
  • Will this contract be renewed?
  • What were the buyer's pain points?
  • Why did Myriad Genetics win?

Free, no account needed

Get to the next one first

This contract's been awarded. We'll find a buyer that plans to buy what you sell, before any tender is published.

Find my next tender early
Save in app

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

Related topics

Topics related to Gene testing and reporting for Ovarian cancer specimens, ranked by notice volume.

View all topics

Related buyers

Buyers similar to NHS Greater Glasgow and Clyde.

View all buyers

Finding public sector work shouldn't be hard

Make your next tender search effortless with Stotles. Set up alerts, find decision maker contacts and never miss a good-fit opportunity again.